Request Information

Tag: regulatory pathways

Clinical Research: Phase 1 - Phase 4

What Patient Population is Participating in Your Early-Phase Gene Therapy Trials? These Factors Could Influence Your Strategy

Today there are over 10,000 rare diseases affecting more than 30 million people in the U.S.1 Many of these disorders are life-threatening, and more than 90% do not have a U.S. FDA-approved treatment2. Novel gene therapies offer hope for improving the health of patients afflicted with these conditions.   Securing clearance for these treatments is...

Read More

Clinical Research: Phase 1 - Phase 4

A Different Pace: Meeting the Demands of Liquid Biopsy Development for Early Cancer Detection

Development of liquid biopsies for early cancer detection requires careful planning. Understanding the regulatory environment and the challenges of conducting the studies needed for approval is integral to success. Here, we review the regulatory pathways for in vitro diagnostics (IVDs) in both the US and the EU and offer strategies for designing and operationalizing large-scale...

Read More

Medical and Regulatory Affairs

Asia-Pacific – Taking Device Clinical Development to the USA and Europe: Understanding the Changes & Leveraging the Opportunity

Medical devices play an increasingly critical role in the health and quality of life for millions of people worldwide. While clinical trials for medical devices have many similarities to those for pharmaceuticals, the regulatory evaluation of devices is distinct from that of drugs – and there are critical differences in the way the device trials...

Read More